The -2518 A/G MCP-1 Polymorphism as a Risk Factor of Inflammatory Bowel Disease
Inflammatory bowel diseases (IBD) are disorders originated from immune disturbances.
The aim of the study was to evaluate the association between the -2518 A/G MCP-1 polymorphism and the risk of IBD development.
Material and methods. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Study group consisted of 197 subjects with IBD (120 with ulcerative colitis and 77 with Crohn's disease) as well as 210 healthy controls.
Results. The presence of the -2518 G/G MCP-1 genotype in the investigated groups seems to be connected with higher risk of inflammatory bowel disease as well as Crohn's disease only (OR 2.26; 95% CI 1.44-3.54 and OR 2.08; 95% CI 1.21-3.46, respectively).
Conclusions. Our data showed that the -2518 A/G MCP-1 polymorphism might be associated with the IBD occurrence and might be used as predictive factor of these diseases in a Polish population.
Labbe K, Danialou G, Gvozdic D et al.: Inhibition of monocyte chemoattractant protein-1 prevents diaphragmatic inflammation and maintains contractile function during endotoxemia. Crit Care 2010; 14: R187.
Yadav A, Saini V, Arora S: MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 2010; 411: 1570-79.
Weber B, Saurer L, Mueller C: Intestinal macrophages: differentiation and involvement in intestinal immunopathologies. Semin Immunopathol 2009; 31: 171-84.
Grimm MC, Elsbury S K, Pavli P et al.: Enhanced expression and production of monocyte chemoattractant protein-1 in inflammatory bowel disease mucosa. J Leukoc Biol 1996; 59: 804-12.
Motomura Y, Ghia JE, Wang H et al.: Enterochromaffin cell and 5-hydroxytryptamine responses to the same infectious agent differ in Th1 and Th2 dominant environments. Gut 2008; 57: 475-81.